Shares of Pharming Group N.V. (PHAR) experienced a significant surge during Wednesday's trading session, soaring 8.93% in response to the company's impressive third-quarter financial results and upward revision of its fiscal year 2025 sales guidance.

The biotechnology company, which focuses on developing protein replacement therapies and precision medicines, reported better-than-expected Q3 financials, catching the attention of investors. Adding to the positive sentiment, Pharming Group raised its FY25 sales guidance above market estimates, signaling strong confidence in its future performance and growth prospects.

This upbeat news has propelled Pharming Group's stock to outperform the broader market, with the surge reflecting investors' enthusiasm for the company's robust financial health and optimistic outlook. As the biotech sector continues to attract attention, Pharming Group's strong performance and raised guidance could potentially position it as a notable player in the industry.